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Background and Aims: Fluid-attenuated inversion recovery (FLAIR) hyperintense
vessels (FHVs) on MRI are a radiological marker of vessel occlusion and indirect sign of
collateral circulation. However, the clinical relevance is uncertain. We explored whether
the extent of FHVs is associated with outcome and how FHVs modify treatment effect
of thrombolysis in a subgroup of patients with confirmed unilateral vessel occlusion from
the randomized controlled WAKE-UP trial.
Methods: One hundred sixty-five patients were analyzed. Two blinded raters
independently assessed the presence and extent of FHVs (defined as the number of
slices with visible FHV multiplied by FLAIR slice thickness). Patients were then separated
into two groups to distinguish between few and extensive FHVs (dichotomization at the
median <30 or ≥30).
Results: Here, 85% of all patients (n = 140) and 95% of middle cerebral artery (MCA)
occlusion patients (n= 127) showed FHVs at baseline. Between MCA occlusion patients
with few and extensive FHVs, no differences were identified in relative lesion growth
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(p = 0.971) and short-term [follow-up National Institutes of Health Stroke Scale (NIHSS)
score; p= 0.342] or long-term functional recovery [modified Rankin Scale (mRS)<2 at 90
days poststroke; p= 0.607]. In linear regression analysis, baseline extent of FHV (defined
as a continuous variable) was highly associated with volume of hypoperfused tissue (β =
2.161; 95% CI 0.96–3.36; p = 0.001). In multivariable regression analysis adjusted for
treatment group, stroke severity, lesion volume, occlusion site, and recanalization, FHV
did not modify functional recovery. However, in patients with few FHVs, the odds for good
functional outcome (mRS) were increased in recombinant tissue plasminogen activator
(rtPA) patients compared to those who received placebo [odds ratio (OR) = 5.3; 95% CI
1.2–24.0], whereas no apparent benefit was observed in patients with extensive FHVs
(OR = 1.1; 95% CI 0.3–3.8), p-value for interaction was 0.11.
Conclusion: While the extent of FHVs on baseline did not alter the evolution of stroke
in terms of lesion progression or functional recovery, it may modify treatment effect and
should therefore be considered relevant additional information in those patients who are
eligible for intravenous thrombolysis.
Clinical Trial Registration: Main trial (WAKE-UP): ClinicalTrials.gov, NCT01525290;
and EudraCT, 2011-005906-32. Registered February 2, 2012.
Keywords: ischemic stroke, FLAIR hyperintensities, thrombolysis, wake-up stroke, prognosis, MRI, hyperintense
vessel
INTRODUCTION
The fluid-attenuated inversion recovery (FLAIR) hyperintense
vessel (FHV) sign is commonly observed on magnetic resonance
imaging (MRI) of acute ischemic stroke patients and is
represented by ipsilateral linear or serpentine hyperintensities
on FLAIR sequences distal to the vessel occlusion (1–6). FHVs
have been shown to be an independent predictor of large
vessel occlusion. However, studies investigating the underlying
pathophysiology and prognostic value of FHVs have yielded
contradictory results (7).
While some have shown that FHVs are associated with
increased collateralization, decreased lesion growth, and
improved long-term functional recovery (6, 8–11), others have
shown that patients with extensive FHVs have increased lesion
growth and worse functional outcome 3 months poststroke
(2, 4, 12, 13). The apparent discrepancies in previous studies
regarding the diagnostic and prognostic value of FHVs may be
due the use of different methodologies in the assessment of FHVs
and inhomogeneous cohorts of patients in terms of treatment in
the acute setting and time to MRI.
The aim of the present study was to investigate whether
the extent of FHVs has an effect on stroke evolution in terms
of lesion progression and long-term functional recovery in a
cohort of acute ischemic stroke patients with middle cerebral
artery (MCA) occlusion and unknown time of onset from the
randomized controlled WAKE-UP trial (14). Furthermore, we
Abbreviations: DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated
inversion recovery; FHV, FLAIR hyperintense vessel; MCA, middle cerebral artery;
ICA, internal carotid artery; MRI, magnetic resonance imaging; mRS, modified
Rankin Scale; NIHSS, National Institutes of Health Stroke Scale (score); OR, odds
ratio; TOF, time-of-flight; PWI, perfusion-weighted imaging.
investigated whether the extent of FHVs on baseline imaging
modifies the treatment effect of thrombolysis and recanalization
rates on follow-up imaging.
METHODS
Patients
This is a retrospective study including patients who were
enrolled in the multicenter, randomized, double-blind, placebo-
controlled WAKE-UP trial (14). Trial patients were randomized
to either treatment with alteplase or placebo. For this analysis,
165 patients with confirmed, unambiguous, unilateral, and
single-vessel occlusion on time-of-flight magnetic resonance
angiography (MRA-TOF) were included. Patients were excluded
from final analysis if baseline FLAIR was not available or not
ratable due to poor image quality.
Clinical Assessment
Demographic data included age, gender, and presence or
previous history of the following cardiovascular risk factors:
smoking, alcohol consumption, arterial hypertension, atrial
fibrillation, hypercholesterolemia, diabetes mellitus type II,
coagulation disorder, transient ischemic attack, ischemic stroke,
and/or intracranial hemorrhage. Clinical assessment comprised
the National Institutes of Health Stroke Scale (NIHSS) on
admission and follow-up (5–9 days poststroke, or if this data
point was not available 22 to 36 h poststroke, considered short-
term outcome in our analysis) as well as good long-term outcome
defined asmodified Rankin Scale (mRS)<2 at 90 days poststroke.
Radiological Assessment
A central image-reading committee reviewed all images
acquired for patient enrollment in the WAKE-UP trial and
Frontiers in Neurology | www.frontiersin.org 2 February 2021 | Volume 11 | Article 623881
Grosch et al. FLAIR Hyperintense Vessels in Acute Stroke
reevaluated imaging inclusion/exclusion criteria assessed by
local investigators. A detailed description of image assessment
within the trial (i.e., measurement of lesion volumes) has been
previously published (14). For the current analysis, all acquired
images were retrospectively reevaluated by two independent
raters (ASG and IG) at the Center for Stroke Research Berlin
at Charite University Hospital Berlin. In this subsample of the
WAKE-UP trial, diffusion-weighted imaging (DWI) and FLAIR
were available for all patients (n = 165) on hospital admission
and in 154 patients (93%) at follow-up (22–36 h after hospital
admission). Lesion volumes were derived from baseline and
follow-up DWI imaging to determine relative (follow-up divided
by baseline DWI lesion volume) and absolute lesion growth
(follow-up subtracted by baseline DWI lesion volume).
We also assessed the evolution of FHVs from baseline to
follow-up FLAIR. We defined that a reduction in FHVs was
present if there was a drop of more than one slice affected
by FHVs between baseline and follow-up imaging. Dynamic
susceptibility contrast perfusion MRI [perfusion-weighted
imaging (PWI)] of diagnostic quality was available in 66 of all
patients (40%), and volumes of hypoperfusion were calculated
using RAPID (https://www.rapidai.com) with a threshold of
Tmax >6 s. PWI–DWI mismatch was defined as an absolute
mismatch volume of >10ml and a mismatch ratio between PWI
and DWI of >1.2. Occlusion site was evaluated on MRA-TOF.
For MCA occlusion analyses, we only included the occlusions
sites ICA+M1, ICA+M2, and M3/M4. Recanalization status was
classified into either complete or no/partial recanalization on
follow-up compared to baseline imaging.
Assessment of FLAIR Hyperintense
Vessels
Blinded to clinical and radiological outcomes, two raters (ASG
and IG) independently rated baseline and follow-up FLAIR
images for the presence and extent of FHVs. FHVs were defined
as linear or serpentine hyperintensities distal to the site of
the occluded vessel (Figure 1). Due to different FLAIR slice
thicknesses of the participating medical centers, the extent of
FHVs was defined as the number of slices with visible FHVs
multiplied by FLAIR slice thickness. Inter-rater agreement for
the presence of FHVs was 95.76% with a free marginal kappa
of 0.92 [95% confidence interval (CI) 0.85–0.98] at baseline and
88.49% with a free marginal kappa of 0.77 (95% CI 0.67–0.87) at
follow-up. The two raters agreed on the extent of FHVs (up to a
maximum difference of one slice) in 52% of all cases. Consensus
was reached for discrepant cases. For further analysis, only
patients with MCA occlusion were separated into two groups to
distinguish between few and extensive FHVs (dichotomization at
the median <30 or ≥30) (1, 2).
Statistical Analysis
Spearman’s rank correlation coefficient was used for correlation
analyses. Based on the scale level of the variables, Mann–
Whitney-U test, Fisher’s exact test, or chi-square test were applied
for two-group analyses. Binary logistic regression analyses
were performed for recanalization (adjustment for reduction in
FHVs, treatment group, and age) as well as for good outcome
defined as mRS <2 at 90 days poststroke (adjustment for
FIGURE 1 | Patient A and Patient B represent two cases at different ends of
the spectrum of the extent of FLAIR hyperintense vessels (FHVs). Patient A is a
69-year-old female with a left-sided M2 branch occlusion and baseline FHV
extent of 60 (multiple linear and serpentine vessels visible surrounding the
operculum and temporal lobe on all three images). Patient B is a 70-year-old
male with a right-sided occlusion in the M2 branch of the middle cerebral
artery whose initial extent of FHVs at baseline was 13 (a single serpentine
vessel is visible between the operculum and the temporal lobe on the middle
image). Both were treated with placebo; the modified Rankin Scale (mRS) at
90 days was 0 for patient A and 3 for patient B. Patients C and D represent
cases with comparable FHV patterns but different stroke extent and severity at
baseline. A comparison of two patients, one a 44-year-old male (patient C) and
the other a 46-year-old female (patient D), both with a left-sided occlusion of
the mainstem middle cerebral artery (MCA). The baseline extent of FHVs was
30 for both cases with a comparable distribution of vessels, yet the stroke
volumes and distributions were different. Patient C showed only small
scattered lesions in the insula, tip of the putamen, as well as the temporal and
parietal lobes (total volume of 3ml), while patient D showed an infarction
encompassing the entire putamen and nucleus caudatus as well as portions of
the insula and operculum, with additionally some scattered lesions in the
frontal and parietal lobes (total volume of 15ml). Their baseline National
Institutes of Health Stroke Scale (NIHSS) score was also different (6 for patient
C and 20 for patient D). At follow-up, both patients recanalized [patient C
received recombinant tissue plasminogen activator (rtPA) and patient D
received placebo]. They had a similar dynamics of FHVs showing a reduction
in their extent (a complete reduction to zero in patient C and a partial reduction
to 12 in patient D). Their mRS outcome at 90 days was 1 for patient C and 3
for patient D.
well-known predictors of outcome including baseline NIHSS
score, recanalization status, treatment group, baseline lesion
volume, occlusion site, FHV group, hours from last seen well to
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treatment). Linear regression analysis was performed for volume
of hypoperfused tissue (adjustment for baseline extent of FHVs)
as well as NIHSS score at follow-up (adjustment for baseline
NIHSS score, recanalization status, treatment group, baseline
lesion volume, occlusion site, FHV group). To investigate the
interaction between the extent of FHVs and treatment effect
on the primary endpoint, we used an unconditional logistic
regression model, relating the log-odds of the primary outcome
with the covariate of interest, the treatment group, and their
interaction, with adjustment on NIHSS score at baseline. The
interaction term was tested with the Wald–chi-square test, and
the treatment effect [odds ratio (OR)] and its 95% CI were
estimated for each category. Statistical analysis was performed




Out of 503 patients enrolled in the WAKE-UP trial, 165 met all
inclusion criteria (328 were excluded due to absence of vessel
occlusion, two due to poor image quality, three due to bilateral
vessel occlusion, five due to unavailable imaging data). The mean
age of this subgroup of patients was 64.2 years, 47% were female,
median NIHSS score at baseline was 9.0 [interquartile range
(IQR) 6.0–15.0]. In total, 85% (n = 140) had FHVs visible on
baseline FLAIR, and median extent of FHVs was 30.0 (IQR
21.3–39.0). Of the 25 patients without baseline FHVs, four had
an occlusion of the internal carotid artery (ICA) (16%), three
of M2 or ICA+M2 (12%), four of M3 or M4 (16%), seven of
the posterior cerebral artery (PCA) (28%), and seven of other
vessels (28%).
Patients With Middle Cerebral Artery
Occlusion
In patients with MCA occlusion (n = 134, 81%), 95% had FHVs
at baseline (n = 127), and the median extent of FHVs was 30.0
(IQR 24.0–40.0). Patients with extensive FHVs did not differ
from patients with few FHVs in terms of baseline DWI lesion
volumes (9.7 vs. 17.5ml; p = 0.218) and baseline NIHSS scores
(12.0 vs. 9.0; p = 0.147). Baseline extent of FHVs (defined as
a continuous variable) was highly associated with the volume
of hypoperfused tissue (β = 2.161; 95% CI 0.96–3.36; p =
0.001), with patients with extensive FHVs having significantly
larger hypoperfused areas at baseline. The occlusion site also
differed significantly between few and extensive FHVs, with
extensive FHVs being associated with proximal vessel occlusions
(p < 0.001). Patients with few and extensive FHVs revealed no
differences in the time between last seen well to MRI (p= 0.261),
last seen well to treatment (p = 0.301), and MRI to treatment (p
= 0.271). Likewise, continuous extent of FHVs did not correlate
with any of the abovementioned variables. In terms of outcome,
there were no differences in relative lesion growth (p = 0.971)
or short-term (p = 0.342) or long-term functional recovery (p =
0.607) between groups (Table 1).
Middle Cerebral Artery Occlusion Patients:
Functional Recovery and Treatment Effect
Univariate regression analysis of long-term functional recovery
revealed merely baseline NIHSS score and recanalization as
predictors. Treatment group, baseline DWI lesion volume,
occlusion site, dichotomized extent of FHVs, and hours from
last seen well to treatment were not identified as independent
predictors in this subgroup analysis. Multivariable regression
analysis confirmed baseline NIHSS score and recanalization
as independent predictors for long-term functional recovery
(Table 2).
When patients were separated into groups based on treatment,
there was a clear trend pointing to the extent of FHVs as a
factor that modifies treatment effect. In patients with FHV extent
<30, only 14% of individuals with a proximal occlusion (M1
segment of the MCA) and 10% with a more distal occlusion (M2,
M3, or M4 segments of the MCA) had good outcome if treated
with placebo, whereas 25 and 46% of patients (with proximal
and distal occlusions, respectively), had good outcome if given
recombinant tissue plasminogen activator (rtPA). Accordingly,
in patients with FHV extent <30, the odds for good outcome
were increased by 5.3 in rtPA-treated patients as compared to
those treated with placebo (OR= 5.3; 95% CI 1.2–24.0), whereas
no apparent benefit of rtPA was observed in patients with FHV
extent≥30 (OR= 1.1; 95% CI 0.3–3.8), p-value for interaction=
0.11. There were no differences in baseline clinical or radiological
parameters (including occlusion site) between patients who
received placebo and those who received rtPA. When the extent
of FHVs was treated as a continuous variable in tPA-treated
patients, the probability of good outcome was relatively stable
across the entire range of FHVs. However, in patients receiving
placebo, there was a very low likelihood of a good outcome
with less prominent FHVs, with chances improving parallel to
increasing FHV extent (Figure 2).
Recanalization and Reduction in FLAIR
Hyperintense Vessels
Overall, the majority of patients (64%; n = 82) experienced a
reduction in FHVs between baseline and follow-up; the median
relative reduction was 50% (ICR 15–100%). In MCA occlusion
patients, the relative extent of reduction was significantly more
pronounced in patients who recanalized as compared to non-
recanalizers (86 vs. 31%; p = 0.001). In binary logistic regression
of MCA occlusion patients, a reduction in FHVs had an adjusted
OR of 5.82 (adjusted for treatment group and age; 95% CI
2.00–16.92; p = 0.001) for successful recanalization on follow-
up. There were only five patients who recanalized but did not
show a reduction in FHVs on follow-up, whereas 33 patients
showed a reduction in FHVs despite persistent vessel occlusion.
Among these non-recanalizers, there was no difference in terms
of absolute lesion progression (21.0 vs. 13.1ml; p = 0.589),
follow-up NIHSS score (9.0 vs. 7.0; p = 0.917), or 3-month mRS
(3.0 vs. 3.0; p= 0.497) between patients who showed a reduction
in FHVs and those who did not (Figure 1).
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TABLE 1 | Demographic data, baseline and follow-up clinical and radiological data for all patients, MCA occlusion patients, MCA occlusion patients with few FHVs, and
MCA occlusion patients with extensive FHVs.
All patients (n = 165) MCA occlusion
patients (n = 134)
MCA occlusion
patients with few
FHVs (n = 53)
MCA occlusion patients with
extensive FHVs (n = 74)
P-value few vs.
extensive FHVs
Age, mean (SD) 64.2 (11.9) 64.5 (11.7) 63.9 (11.6) 64.9 (11.9) 0.514
Female sex, % (n) 47% (77) 49% (66) 38% (20) 54% (41) 0.049
Previous history of CVRF, % (n)
- Arterial hypertension 49% (80) 49% (65) 48% (25) 48% (35) 0.988
- Atrial fibrillation 17% (27) 19% (25) 9% (5) 25% (18) 0.036
- TIA 3% (5) 3% (4) 6% (3) 1% (1) 0.307
- Ischemic stroke 10% (16) 9% (12) 9% (5) 7% (5) 0.741
- Intracranial hemorrhage 0% (0) 0% (0) 0% (0) 0% (0) 1.000
- Hypercholesterolemia 36% (56) 37% (47) 42% (21) 33% (23) 0.306
- Diabetes mellitus type II 13% (21) 15% (19) 15% (8) 13% (9) 0.792
- Coagulation disorder 0% (0) 0% (0) 0% (0) 0% (0) 1.000
- Gastrointestinal bleeding 2% (3) 2% (3) 6% (3) 0% (0) 0.066
- Current smoking 31% (48) 31% (40) 22% (11) 38% (27) 0.080
- Alcohol 39% (59) 41% (52) 41% (20) 44% (31) 0.707
FHV on admission
- % (n) 85% (140) 95% (127) 100% (53) 100% (74) 1.000
- Median extent (IQR) 30.0 (21.3–39.0) 30.0 (24.0–40.0) 22.0 (17.5–25.0) 39.0 (30.0–48.0) <0.001
Reduction in FHVs between baseline and follow-up imaging
- Absolute, median (IQR) 15.0 (5.0–25.0) 15.0 (5.0–25.0) 14.0 (2.7-24.0) 15.0 (6.0-30.0) 0.059
- Relative, median (IQR) 50% (15%−100%) 50% (16%−100%) 100% (14%−100%) 40% (16%−83%) 0.040
ASPECTS mismatch, % (n) 73% (97) 73% (93) 59% (31) 84% (62) 0.002
NIHSS score
- Baseline, median (IQR) 9.0 (6.0–15.0) 10.0 (6.0–15.5) 9.0 (6.0–14.0) 12.0 (7.0–16.0) 0.147
- Follow-up, median (IQR) 6.0 (2.0–13.3) 6.0 (1.5–13.0) 6.0 (1.0–10.0) 8.0 (2.0–15.0) 0.342
MRS at 90 days
- Median (IQR) 3.0 (1.0–4.0) 3.0 (1.0–4.0) 3.0 (1.0–3.0) 3.0 (1.0–4.0) 0.255
- Good outcome, % (n) 26% (42) 27% (36) 39% (16) 26% (19) 0.607
DWI lesion volume in ml
- Baseline, median (IQR) 9.8 (3.1–24.0) 10.4 (4.7–25.9) 17.5 (4.8–31.8) 9.7 (4.4–22.1) 0.218
- Follow-up, median (IQR) 21.9 (5.6–59.0) 23.1 (6.2–57.6) 29.7 (5.7–60.0) 21.3 (6.1–54.7) 0.653
DWI lesion growth in %
- Absolute, median (IQR) 10.6 (1.1–38.3) 12.2 (1.9–36.2) 11.8 (1.7–36.2) 12.8 (1.6–37.0) 0.746
- Relative, median (IQR) 121% (37–320%) 121% (28–254%) 114% (14–253%) 121% (31–276%) 0.971
Treatment with rtPA, % (n) 50% (83) 50% (67) 57% (30) 45% (33) 0.186
Occlusion site, % (n) <0.001
- ICA 6% (9) 0% (0) 0% (0) 0% (0)
- ICA+M1 or M1 39% (64) 48% (64) 28% (15) 66% (49)
- ICA+M2 or M2 27% (45) 34% (45) 45% (24) 24% (18)
- M3/M4 15% (25) 19% (25) 26% (14) 10% (7)
- PCA 9% (14) 0% (0) 0% (0) 0% (0)
- Other 5% (8) 0% (0) 0% (0) 0% (0)
Recanalization, % (n) 36% (49) 41% (45) 46% (19) 34% (21) 0.204
PWI-DWI mismatch, % (n) 65% (42) 78% (38) 72% (18) 83% (19) 0.499
PWI volume, median (IQR) 50.7 (26.0–89.7) 64.4 (30.2–95.1) 49.0 (29.3–72.3) 74.8 (50.3–109.2) 0.047
Hours from LSW to MRI, median (IQR) 10.0 (6.8–11.8) 10.1 (6.9–11.9) 10.1 (6.3–11.5) 10.2 (7.3–12.9) 0.261
Hours from LSW to treatment, median (IQR) 10.5 (7.4–12.4) 10.6 (7.5–12.5) 10.5 (6.9–12.1) 10.7 (7.6–13.4) 0.301
Hours from MRI to treatment, median (IQR) 0.4 (0.3–0.6) 0.4 (0.3–0.6) 0.4 (0.2–0.6) 0.5 (0.3–0.6) 0.271
P-values are given for group comparisons between patients with few and extensive FHVs.
MCA, middle cerebral artery; FHV, FLAIR hyperintense vessel; SD, standard deviation; n, number; CVRF, cardiovascular risk factors; IQR, interquartile range; ASPECTS, Alberta stroke
program early CT score; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; DWI, diffusion-weighted imaging; rtPA, recombinant tissue plasminogen
activator; ICA, internal carotid artery; M1, M1 segment of the MCA; M2, M2 segment of the MCA, M3/M4, M3 or M4 segment of the MCA; PCA, posterior cerebral artery; PWI,
perfusion-weighted imaging; LSW, last seen well. The bold values indicate the statistical significance (i.e., p < 0.05).
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TABLE 2 | Univariate and multivariable regression analyses for good outcome (mRS <2) 3 months poststroke in MCA occlusion patients.
Univariable logistic regression Multivariable logistic regression
Crude odds ratio (95% CI) P-value Adjusted odds ratio (95% CI) P-value
Baseline NIHSS score 0.768 (0.687; 0.858) <0.001 0.753 (0.647; 0.878) <0.001
Recanalization 3.873 (1.578; 9.508) 0.003 3.922 (1.147; 13.404) 0.029
Treatment group 1.618 (0.746; 3.506) 0.223 1.948 (0.584; 6.494) 0.278
Small baseline DWI lesion volume 0.971 (0.942; 1.000) 0.051 1.000 (0.958; 1.043) 0.988
Occlusion site (more distal) 1.405 (0.856; 2.306) 0.178 0.665 (0.272; 1.626) 0.371
FHV group (few vs. extensive) 0.814 (0.371; 1.785) 0.607 1.123 (0.308; 4.091) 0.861
Hours from LSW to treatment 0.973 (0.897; 1.054) 0.498 1.039 (0.922; 1.170) 0.528
NIHSS, National Institutes of Health Stroke Scale; 95% CI, 95% confidence interval; DWI, diffusion-weighted imaging; FHV, FLAIR hyperintense vessel; mRS, modified Rankin Scale;
LSW, last seen well; MCA, middle cerebral artery. The bold values indicate the statistical significance (i.e., p < 0.05).
FIGURE 2 | Predicted probability of good clinical outcome [modified Rankin Scale (mRS) < 2] in patients grouped according to treatment, plotted against the extent
of FLAIR hyperintense vessels (FHVs) on baseline imaging. The continuous blue line represents recombinant tissue plasminogen activator (rtPA)-treated patients, and
the dotted red line stands for patients who received placebo.
DISCUSSION
In the current study, the extent of FHVs on baseline imaging
did not alter stroke progression in terms of initial stroke severity,
lesion growth, or long-term functional recovery in patients with
MCA occlusion and unknown time of symptom onset. However,
patients with less pronounced FHVs had higher odds of achieving
a good outcome following treatment with rtPA. In other words,
the extent of FHVs assessed on acute imaging may modify the
treatment effect of thrombolysis.
In line with previous studies (2, 4, 11), here, 85% of ischemic
stroke patients with proven vessel occlusion presented with FHVs
ipsilateral to the ischemic lesion on baseline imaging. Extent of
FHVs correlated directly with the volume of hypoperfused tissue.
This is likely in part due to the higher rates of proximal occlusions
observed in patients with extensive FHVs (Table 1). Similar
results were previously reported, showing an association between
FHVs and more severe hypoperfusion (2) and identifying FHV
as an independent predictor of a perfusion–diffusion mismatch
in the case of vessel occlusion (15, 16).
In our study, the extent of FHVs had no effect on clinical
stroke severity or lesion size on admission, nor did it modify
lesion progression or functional recovery (Table 1). This matches
the results of a recently published systematic review of FHVs in
ischemic stroke (7); in a pooled sample of over 3,000 patients,
there was no association between functional outcome and extent
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FIGURE 3 | Patients A and B represent cases with comparable stroke evolution yet differing evolution of FLAIR hyperintense vessels (FHVs) between baseline and
follow-up imaging. Both 64-year-old males with a right-sided M1 occlusion. Patient A additionally had an occlusion of the ipsilateral internal carotid artery (ICA). The
baseline lesions were comparable in terms of volume and pattern (predominantly basal ganglia involvement and lesion size up to 20ml). Their baseline National
Institutes of Health Stroke Scale (NIHSS) score was also comparable (15 for patient A and 14 for patient B). The baseline extent of FHVs was different between the
patients (30 in patient A and 50 in patient B). Both patients received placebo, and neither of them experienced a recanalization by the time of follow-up. There was a
pronounced difference in the dynamics of FHVs between the patients, with patient A showing no more visible FHVs at follow-up, whereas the extent of FHVs in patient
B actually increased from 50 to 55. Their outcome, however, was the same (both had a 90-day mRS of 4), and their final lesion volumes were almost identical (patient
A 52ml and patient B 59ml).
of FHVs. To further illustrate this, in our cohort, we found
examples of patients with matching occlusions, similar lesion
extent, and severity of stroke who presented with very different
extents of FHVs at baseline as well as the opposite (patients with
identical occlusions and similarly pronounced FHVs yet different
clinical and imaging stroke severities) (Figure 3).
Interestingly, the extent of baseline FHVs modified treatment
effect, with thrombolysis being more effective in patients with
fewer visible collaterals, and especially so if they had a more
distally placed vessel occlusion. Although patients with large
vessel occlusions still benefit from intravenous thrombolysis,
previous studies have shown that the presence of a proximally
placed vessel occlusion is associated with worse outcome
following intravenous thrombolysis (17) (additional REF). At
the same time, for patients receiving placebo, higher likelihoods
of good clinical outcome were found in individuals with
more pronounced FHVs (Figure 2). This might point to a
protective component of prominent FHVs, at least in the
initial hours after occlusion occurs, with patients who are
unable to quickly recruit an extensive collateral network being
that much more dependent on therapy for a chance at good
functional outcome. The generalizability of these results to
different patient populations, i.e., to ischemic stroke patients
with large vessel occlusion eligible for endovascular therapy
should be viewed with caution. According to the clinical and
radiological criteria of the DAWN and DEFUSE 3 trials, these
patients would be candidates for direct endovascular therapy
(18, 19). However, a better understanding of rtPA efficacy in
patients with unknown symptom onset and extensive FHVs
could be particularly valuable in selecting patients who might
benefit from a bridging therapy with rtPA before endovascular
therapy. Larger independent cohort analyses on this topic are
warranted to validate our findings.
In this study, treatment with tPA did not reach statistical
significance for good outcome 90 days poststroke in the overall
cohort (Table 2). This is most likely due to the smaller sample size
of the current study; point estimates for treatment were similar in
this analysis (crude OR of 1.62) to those reported in the original
trial analysis (crude OR 1.6) (14).
It is known that FHVs are a transient MRI phenomenon
and typically disappear by 36 h poststroke (5, 20, 21). Similar
to previous studies, we observed an overall reduction of FHVs
over time in ∼64% of patients (5, 22), and this reduction was
independently associated with successful recanalization. In other
words, early reduction in FHVs may be a surrogate marker
of successful recanalization and hence be associated with less
stroke progress and better functional recovery. However, in the
case of persistent vessel occlusion, a reduction in FHVs was
not associated with a smaller lesion growth or better functional
recovery (Figure 1).
Interestingly, there were significantly more females in the
group of patients with MCA occlusion and extensive FHVs
(Table 1). Previous studies have described sex-specific differences
in cerebrovascular parenchymal hyperintensities on FLAIR (23)
(additional REF). However, to the best of our knowledge,
previous studies on FHVs have not observed sex-specific
differences in terms of the extent of FHVs in the setting of acute
stroke. Future analyses on this topic would be of great interest.
Based on previous studies and our current analysis, it is clear
that FHVs are radiological markers of proximal vessel occlusion.
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They most likely represent arteries distal to the occlusion site
exhibiting slow flow (owing to a collateral circulation that is
sufficient enough to provide retrograde flow but insufficient to
achieve the extent of perfusion present prior to the stroke and
therefore associated with the size of the perfusion deficit (2, 5, 12).
This, however, is not to say that FHVs indicate hypoperfusion
below the ischemia threshold leading to tissue infarction, as
their presence and magnitude seem to confer a certain protective
advantage to the tissue—an advantage that, as many studies have
shown (7), is neither unequivocal nor easy to understand. In this
they are not alone, as other MRI markers (for example, dynamic
susceptibility contrast MRI, also known as perfusion imaging)
have failed to deliver an indisputable parameter and/or threshold
that reliably predicts tissue fate (24). The reason might lie in
the highly dynamic evolution of an acute ischemic stroke; the
timely unfolding of several factors, such as treatment, changes
in antegrade flow (the extent of recanalization), and retrograde
flow (the continuous improvement of collateral circulation), but
also different tissue susceptibilities to ischemia collectively play
crucial roles in determining tissue fate. Therefore, any given
MRI must be seen as a snapshot of the current situation, which
is inevitably destined to undergo change and can hence only
partially be predictive of future outcome.
There are several limitations of this study. First, due to
its retrospective nature and small numbers, we run the risk
of type II error in our analysis. Furthermore, PWI was only
available in a limited number of our patients, and no gold
standard information on collateral status exists for this cohort.
In addition, information pertaining to stroke etiology as well
as thrombus composition is also lacking in our cohort. In
addition, this cohort comprises patients treated with tPA and
placebo, and adjustment for treatment group in multivariable
regression analyses only partially compensates for this limitation
of a heterogeneous cohort. However, this is the first study to
investigate the diagnostic and prognostic value of FHVs in a
cohort of patients stemming from a multinational, randomized,
placebo-controlled trial.
In summary, FHVs may serve as a surrogate marker of
large vessel occlusion and successful activation of collaterals
to increase blood flow to hypoperfused tissue; in turn, early
reduction of FHVs is also an independent predictor of successful
recanalization. Although there is no clear clinical relevance for
the extent of FHV alone in terms of functional recovery, FHVs
may modify treatment effect of thrombolysis. In other words,
patients with less pronounced FHVs on acute imaging seem to
profit from rtPAmore.Wemaintain that this frequently observed
MRI parameter should not guide treatment decisions based on
current findings and that a validation in a larger independent
cohort is warranted. However, FHVs may serve as an additional
piece of information in selecting patients with confirmed vessel
occlusion for intravenous thrombolysis or bridging therapy
before endovascular treatment.
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